The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
Open accessAbstract
SUMMARY Background Based on the encouraging activity and manageable safety profile observed in a phase 1 study, the ECHELON-2 trial was initiated to compare the efficacy and safety of brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) versus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) for the treatment of CD30-positive peripheral T-cell lymphomas (PTCL). Methods ECHELON-2 (ClinicalTrials.gov No. NCT01777152) is a double-blind, double-dummy, randomised, placebo-controlled, active-comparator phase 3 study. Eligible adults with previously-untreated CD30-positive PTCL (targeting 75% with systemic anaplastic large cell lymphoma [sALCL]) were randomised 1:1 to receive either A+CHP or CHOP for six or eight 21-day cycles. All subjects received cyclophosphamide 750 mg/m2 and doxorubicin 50 mg/m2 on Day 1 of each cycle intravenously (IV) and prednisone 100 mg daily on Days 1 to 5 of each cycle orally, followed by either brentuximab vedotin 1·8 mg/kg and placebo form of vincristine on Day 1 of each cycle IV (A+CHP arm) or vincristine 1·4 mg/m2 and placebo form of brentuximab vedotin IV (CHOP arm). Randomization was stratified by histological subtype as per local pathology assessment and by international prognostic index (IPI) score. The primary endpoint, progression-free survival (PFS) per blinded independent central review, was analysed by the intent-to-treat. Findings A total of 452 subjects were enrolled between January 24, 2013 and November 07, 2016 and 226 subjects were randomly assigned to each arm. The hazard ratios of both the PFS (0·71 [95% CI: 0·54, 0·93], p=0·0110) and overall survival (OS) (0·66 [95% confidence interval {CI}: 0·46, 0·95], p=0·0244) favoured A+CHP over CHOP. The median PFS was 48·2 months (95% CI: 35·2, not evaluable) versus 20·8 months (95% CI: 12·7, 47·6), for A+CHP and CHOP, respectively. The median was not met for OS. Adverse events (AEs), including incidence and severity of febrile neutropenia (in 41 subjects (18%) in A+CHP arm and 33 (15%) in CHOP) and peripheral neuropathy (in 117 subjects (52%) in A+CHP arm and 124 (55%) in CHOP), were similar between arms. Fatal AEs occurred in 7 subjects (3%) in the A+CHP arm and 9 subjects (4%) in the CHOP arm. Interpretation Frontline treatment with A+CHP is superior to CHOP for subjects with CD30-positive PTCL as demonstrated by a statistically significant improvement in PFS and OS with a manageable safety profile. Funding Supported by Seattle Genetics, Inc. and Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. This research was funded in part through the National Institutes of Health/National Cancer Institute Cancer Center Support Grant P30 CA008748.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
Revised Response Criteria for Malignant Lymphoma
Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,426
Self-citationWHO classification of haematolymphoid tumours
Gaillard, F., Weerakkody, Y., & Sharma, R. (2010) · Radiopaedia.org · doi:10.53347/rid-9250 · Cited by 3,776
A note on quantifying follow-up in studies of failure time
Schemper, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,575
International T-Cell Lymphoma Project (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.4558 · Cited by 2,108
Savage, K. J., Harris, N. L., Vose, J. M., Ullrich, F., Jaffe, E. S., Connors, J. M., Rimsza, L., Pileri, S. A., Chhanabhai, M., Gascoyne, R. D., et al. (2008) · Blood · doi:10.1182/blood-2008-01-134270 · Cited by 863
Self-citationAnderson, J. R., Armitage, J. O., & Weisenburger, D. D. (1998) · Annals of Oncology · doi:10.1023/a:1008265532487 · Cited by 674
Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01
d'Amore, F., Relander, T., Lauritzsen, G. F., Jantunen, E., Hagberg, H., Anderson, H., Holte, H., Österborg, A., Merup, M., Brown, P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.2719 · Cited by 594
Self-citationWeisenburger, D. D., Savage, K. J., Harris, N. L., Gascoyne, R. D., Jaffe, E. S., MacLennan, K. A., Rüdiger, T., Pileri, S., Nakamura, S., Nathwani, B., et al. (2011) · Blood · doi:10.1182/blood-2010-09-310342 · Cited by 431
Self-citationReimer, P., Rüdiger, T., Geissinger, E., Weissinger, F., Nerl, C., Schmitz, N., Engert, A., Einsele, H., Müller-Hermelink, H. K., & Wilhelm, M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.4870 · Cited by 427
Self-citation
Cited by
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
Tilly, H., Morschhauser, F., Sehn, L. H., Friedberg, J. W., Trněný, M., Sharman, J. P., Herbaux, C., Burke, J. M., Matasar, M., Rai, S., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2115304 · Cited by 926
Self-citationAntibody–drug conjugates come of age in oncology
Dumontet, C., Reichert, J. M., Senter, P. D., Lambert, J. M., & Beck, A. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00709-2 · Cited by 842
Antibody–drug conjugates for cancer
Chau, C. H., Steeg, P. S., & Figg, W. D. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31774-x · Cited by 816
Emerging new therapeutic antibody derivatives for cancer treatment
Jin, S., Sun, Y., Liang, X., Gu, X., Ning, J., Xu, Y., Chen, S., & Pan, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00868-x · Cited by 459
CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
Zhang, X., Zhu, L., Zhang, H., Chen, S., & Xiao, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.927153 · Cited by 396
Metadata
- Authors
- Horwitz, S., O'Connor, O. A., Pro, B., Illidge, T., Fanale, M., Advani, R., Bartlett, N. L., Christensen, J. H., Morschhauser, F., Domingo-Domenech, E., Rossi, G., Kim, W. S., Feldman, T., Lennard, A., Belada, D., Illés, Á., Tobinai, K., Tsukasaki, K., Yeh, S.-P., Shustov, A., Hüttmann, A., Savage, K. J., Yuen, S., Iyer, S., Zinzani, P. L., Hua, Z., Little, M., Rao, S., Woolery, J., Manley, T., Trümper, L., Aboulafia, D., Advani, R., Alpdogan, O., Ando, K., Arcaini, L., Baldini, L., Bellam, N., Bartlett, N., Belada, D., Yehuda, D. B., Benedetti, F., Borchman, P., Bordessoule, D., Brice, P., Briones, J., Caballero, D., Carella, A. M., Chang, H., Cheong, J. W., Cho, S.-G., Choi, I., Choquet, S., Colita, A., Congui, A. G., D'amore, F., Dang, N., Davison, K., de Guibert, S., Brown, P. D. N., Delwail, V., Demeter, J., di Raimondo, F., Do, Y. R., Domingo, E., Douvas, M., Dreyling, M., Ernst, T., Fanale, M., Fay, K., Feldman, T., Ferrero, S. F., Flinn, I. W., Forero-Torres, A., Fox, C., Friedberg, J., Fukuhara, N., Garcia-Marco, J., Cruz, J. G., Codina, J. G., Gressin, R., Grigg, A., Gurion, R., Christensen, J. H., Haioun, C., Hajek, R., Hanel, M., Hatake, K., Hensen, R., Horowitz, N., Horwitz, S., Huttmann, A., Illes, A., Illidge, T., Ishizawa, K., Islas-Ohlmayer, M., Jacobsen, E., Janakiram, M., Jurczak, W., Kaminski, M., Kato, K., Kim, W. S., Kirgner, I., Iyer, S., Kuo, C.-Y., Lazaroiu, M. C., Du, K. L., Lee, J.-S., LeGouill, S., Lennard, A., LaRosee, P., Levi, I., Link, B., Maisonneuve, H., Maruyama, D., Mayer, J., McCarty, J., McKay, P., Minami, Y., Mocikova, H., Morra, E., Morschhauser, F., Munoz, J., Nagai, H., O'Connor, O., Opat, S., Pettengell, R., Pezzutto, A., Pfreundschuh, M., Pluta, A., Porcu, P., Pro, B., Quach, H., Rambaldi, A., Renwick, W., Reyes, R., Izquierdo, A. R., Rossi, G., Ruan, J., Rusconi, C., Salles, G., Santoro, A., Sarriera, J., Savage, K., Shibayama, H., Shustov, A., Suh, C., Sureda, A., Tanimoto, M., Taniwaki, M., Tilly, H., Tobinai, K., Trneny, M., Trumper, L., Tsukamoto, N., Tsukasaki, K., Vitolo, U., Walewski, J., Weidmann, E., Wilhelm, M., Witzens-Harig, M., Yacoub, A., Yamamoto, K., Yeh, S.-P., Yoon, S.-S., Yuen, S., Yun, H. J., Zain, J., & Zinzani, P. L.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 393
- Issue
- 10168
- Pages
- 229-240
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2903308035
- Cited by
- 739
- References
- 17
- FWCI
- 49.01
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(18)32984-2
- The paper
- Horwitz, S., O'Connor, O. A., Pro, B., Illidge, T., Fanale, M., Advani, R., Bartlett, N. L., Christensen, J. H., Morschhauser, F., Domingo-Domenech, E., Rossi, G., Kim, W. S., Feldman, T., Lennard, A., Belada, D., Illés, Á., Tobinai, K., Tsukasaki, K., Yeh, S.-P., . . . Zinzani, P. L. (2019). Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. The Lancet. https://doi.org/10.1016/s0140-6736(18)32984-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.